Study of NAT2 gene polymorphisms in an Indian population: Association with plasma isoniazid concentration in a cohort of tuberculosis patients

Molecular Diagnosis and Therapy

Volumn 13, Issue 1, 2009, Pages 49-58

  Singh, Neera ^a   Dubey, Sudhisha ^a   Chinnaraj, Saravanan ^a   Golani, Anil ^a   Maitra, Anurupa ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TUBERCULOSIS;

EID: 64349099779     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256314     Document Type: Article

References (50)

1. Hughes HB, Biehl JP, Jones AP, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70: 266-73
2. Evans DA, Manley KA, Mckuscik VA. Genetic control of isoniazid metabo- lism in man. Br Med J 1960; 2: 485-91
3. Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Publ 1999; 148: 251-70
4. Pawlik A, Ostanek L, Brzosko I, et al. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther 2002; 72: 319-25
5. Chaudhary S, Behari M, Dihana M, et al. Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians. Pharmacogenet Genomics 2005; 15:731-75
6. Machida H, Tsukamoto K, Wen CY, et al. Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene. World J Gastroenterol 2005; 11: 4833-7
7. Kubota R, Ohno M, Hasunuma T, et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 2007; 63: 927-33
8. WHO. Global tuberculosis control: surveillance, planning, financing. WHO report no. WHO/HTM/TB/2008.393. Geneva: WHO, 2008 [online]. Available from URL: http://www.who.int/tb/publications/global-report/2008/pdf/ fullreport.pdf [Accessed 2008 Feb 19]
9. Steinbrook R. Tuberculosis and HIV in India. N Engl J Med 2007; 356: 1198-9
10. Hiratsuka M, Kishikawa Y, Takekuma Y, et al. Genotyping of the N- acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002; 17: 357-62
11. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37
12. Suzuki H, Morris JS, Li Y, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 1184-91
13. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-22
14. Cascorbi I, Brockmöller J, Bauer S, et al. NAT2* 12A (803AG) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996; 6: 257-9
15. Hein DW. Human NAT2 alleles [online]. Available from URL: http:// N-acetyltransferasenomenclature.louisville.edu [Accessed 2008 Jan 22]
16. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism fre- quencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-48
17. Patin E, Barreiro LB, Sabeti PC, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006; 78: 423-36
18. Butcher NJ, Boukouvala S, Sim E, et al. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002; 2: 30-42
19. Lee SY, Lee KA, Ki CS, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 2002; 48: 775-7
20. Jain M, Kumar S, Lal P, et al. Association of genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal cancer in north Indian population. Cancer Invest 2007; 25: 340-6
21. Mittal RD, Srivastava DS, Mandhani A. NAT2 gene polymorphism in bladder cancer: a study from North India. Int Braz J Urol 2004; 30: 279-85
22. Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol 2005; 5: 12
23. Arif E, Vibhuti A, Alam P, et al. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007; 382: 37-42
24. Babu KA, Rao KL, Reddy NG, et al. N-acetyl transferase 2 polymorphism and advanced stages of endometriosis in South Indian women. Reprod Biomed Online 2004; 9: 533-40
25. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of south India. Int J Mol Med 2003; 11: 125-31
26. Doll MA, Fretland JF, Deitz AC, et al. Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele-specific amplification. Analyt Biochem 1995; 231: 413-20
27. Singh N, Golani A, Patel Z, et al. Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. Br J Clin Pharmacol 2008; 65: 418-22
28. Thomann P. Non-compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, editors. TopFit 2.0 pharmacokinetic and pharma-codynamic data analysis system for the PC. Stuttgart: Gustav Fischer, 1993: 5-66
29. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 5: 1162-9
30. HAP-Haplotype analysis tool [online]. Available from URL: http:// research.calit2.net/hap/WebServer.htm [Accessed 2008 Nov 14]
31. Barrett JC, Fry B, Mailer J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5
32. Rychlik-Sych M, Skretkowicz J, Gawroñska-Szklarz B, et al. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 2006; 58: 22-9
33. Tanigawara Y, Kita T, Aoyama N, et al. N-acetyltransferase 2 genotype- related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002; 25: 1058-62
34. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17: 459-64
35. Morton LM, Schenk M, Hein DW, et al. Genetic variation in N- acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 2006; 16: 537-45
36. Bu R, Gutiérrez MI, Al-Rasheed M, et al. Variable drug metabolism genes in Arab population. Pharmacogenomics J 2004; 4: 260-6
37. Loktionov A, Moore W, Spencer SP, et al. Differences in N-acetylation geno- types between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 2002; 26: 15-22
38. ChenB, Li JH, XuYM, et al. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta 2006; 365: 104-8
39. Yuliwulandari R, Sachrowardi Q, Nishida N, et al. Polymorphisms of pro- moter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genet 2008; 53: 201-9
40. Kukongviriyapan V, Prawan A, Tassaneyakul W, et al. Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol 2003; 55:278-81
41. Torkaman-Boutorabi A, Hoormand M, Naghdi N, et al. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol 2007; 34: 1207-11
42. Schnakenberg E, Ehlers C, Feyerabend W, et al. Genotyping of the poly- morphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin Genet 1998; 53: 396-402
43. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976; 19: 610-25
44. Kinzig-Schippers M, Tomalik-Scharte D, letter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49: 1733-8
45. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9
46. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Mon 1998; 20: 469-72
47. Meyers FH, Jawetz E, Goldfien A. Review of medical pharmacology, 5th ed. Los Altos (CA): Lange Medical Publications, 1976
48. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005; 90: 551-3
49. Conte Jr JE, Golden JA, McQuitty M, et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother 2002; 46: 2358-64
50. Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64: 673-81